Assertio Acquired by Zydus Worldwide | Healthcare M&A Deal

Zydus Worldwide has completed the acquisition of Assertio, a pharmacy business in the United States, for $166.4 million. Assertio Holdings develops Rolvedon, a chemotherapy supportive care drug used to reduce infection risk in cancer patients, with about $68 million in 2025 sales. Zydus Worldwide acquisitions in healthcare M&A aim to strengthen its oncology and supportive-care portfolio through this merger acquisition. The strategic acquisition follows Assertio’s acceptance of a new buyout bid at $23.50 per share, replacing an earlier Garda Therapeutics offer, and is expected to close in Q2 with no contingencies or outside financing.